Journal
ONCOIMMUNOLOGY
Volume 3, Issue 1, Pages -Publisher
LANDES BIOSCIENCE
DOI: 10.4161/onci.27296
Keywords
adaptive immunity; CD4; CD40; CD40L; CD8; HER2; Herceptin; antibody; immunotherapy; neu
Categories
Funding
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007090] Funding Source: NIH RePORTER
- NCI NIH HHS [R01 CA141975, P01 CA097296] Funding Source: Medline
- NIAID NIH HHS [T32 AI007090] Funding Source: Medline
Ask authors/readers for more resources
Preclinical studies have established that CD8(+) T cells are necessary for efficient immunotherapeutic regimens targeting v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ER BB2, best known as HER 2/Neu). Recently, we extended upon these findings by demonstrating that anti-HER 2/Neu therapy also requires CD4(+) T cells and CD40/CD40L signaling within the tumor microenvironment. Our results add to mounting evidence demonstrating that adaptive immunity is crucial to the efficacy of conventional and targeted anticancer chemotherapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
